Are hip regeneration clinics legitimate when care uses part of your body?

What should the clinic explain?

The clinic should name its best current explanation for the soreness. It should also say what the treatment contains and who gives it.

Ask what a reasonable amount of improvement would mean for walking, sleep or stairs. A broad promise doesn't answer how much daily life might change.

The person doing the exam should ask about health risks and past care. Get a name and phone number for questions or problems after the visit.

How can you check a treatment claim?

Ask whether the claim came from people with the same sore hip area. A report about knees can't show what will happen in a hip.

Government approval of a blood-spinning machine only covers the machine and its stated use. It doesn't prove that the prepared blood will ease a sore hip.

Ask how much change the clinic expects, what could go wrong and what care follows. The answer should cover your hip, not joints in general.

What should make you slow down?

Slow down when a price ends before there's time to read the papers. Be wary when a success rate doesn't name which patients were counted or when they were checked.

Don't sign while basic questions remain open or no one has examined the hip. A clear offer can stand up to questions and another doctor's view.

Write down the clinic's answers before leaving. Later, compare those answers with the care and price listed in the papers.

Sources

1. FDA states verbatim that regenerative medicine products including stem cells, stromal vascular fraction, umbilical cord blood, Wharton's jelly, amniotic fluid and exosomes have NOT been approved 'for the treatment of any orthopedic condition, such as osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain, or shoulder pain.' The only FDA-approved stem cell products in the United States are blood-forming (hematopoietic progenitor) cells derived from umbilical cord blood, approved only for disorders affecting blood production.

   U.S. Food and Drug Administration — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes.. FDA, 2026.

2. In January 2025 federal court orders permanently banned the co-founders of the Stem Cell Institute of America and related companies from marketing stem cell therapy, and required payment of $5,155,146 in civil penalties and consumer refunds. The court found on summary judgment that the defendants published false and misleading advertisements about the efficacy and approval of stem cell injection treatments for conditions including osteoarthritis and joint pain.

   Federal Trade Commission — Stem Cell Institute Co-Founders and Companies Banned from Marketing Stem Cell Treatments, Ordered to Pay More than $5.1 Million.. FTC, 2025.

3. A 2016 analysis of internet marketing found widespread direct-to-consumer promotion of unapproved stem cell interventions by businesses based in the United States - not only in countries with lax regulation - and concluded that regulators must better oversee this marketplace.

   Turner L, Knoepfler P — Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry.. Cell Stem Cell, 2016. DOI: 10.1016/j.stem.2016.06.007.

4. A 2025 review of mesenchymal stem cell injection research in orthopaedics identified 449 registered clinical trials, of which only 159 (35.4%) were complete and only 56 (12.5%) had published results in peer-reviewed journals. Hip and knee osteoarthritis were the most common indications (37.6%). Reported cell concentrations spanned three orders of magnitude and 55.5% of protocols did not specify a concentration at all.

   Bezuglov E, et al. — Mesenchymal stem cells injections in traumatology and orthopaedics: common practice or still a promising area with many uncertainties?. BMC Musculoskeletal Disorders, 2025. DOI: 10.1186/s12891-025-09123-8.